Physician profile
Xiaodan Zhou
NPI 1841956034
$1,737.68
in general payments reported to CMS, 2019-2025
22 companies · $709 in 2025
The $709 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.39 · 2023: $395 · 2024: $601 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $230.94 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.67 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $178.82 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $171.94 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $137.44 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $96.36 | 2023-2025 | Repatha |
| Pfizer INC. | $91.70 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.39 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $82.66 | 2024-2025 | Wegovy, Ozempic |
| Cvrx, INC. | $74.03 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $53.43 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $48.85 | 2024-2025 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $43.87 | 2023-2024 | Inpefa |
| Exact Sciences Corporation | $40.54 | 2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $39.56 | 2024-2025 | Slynd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $38.27 | 2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $33.54 | 2024 | Optimizer |
| Boston Scientific Corporation | $28.76 | 2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.01 | 2024 | Voquezna |
| Lilly USA, LLC | $13.52 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaodan Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.